Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of...
August 22 2018 - 7:00AM
Key Opinion Leaders gather to discuss: LDL-c:
Done Deal, Next Epigenetics?Dr. Ewelina Kulikowski of Resverlogix
to present data on the effect of apabetalone on vascular
inflammation
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today
announced it is supporting a satellite symposium on August 25th,
2018, at the European Society of Cardiology Congress 2018 in
Munich, Germany, titled: LDL-c: Done Deal, Next Epigenetics?
Satellite Symposium Agenda
15:30 - 15:35 (local time): IntroductionUlrich Laufs, MD –
Leipzig, Germany
15:35 - 15:50: The real residual risk in patients with CVD &
diabetes: The promise of epigeneticsErik Stroes, MD – Amsterdam,
Netherlands
15:50 - 16:10: Understanding epigenetics: The potential
rationale for BET inhibition in management of CVDJorge Plutzky, MD
– Boston, USA
16:10 - 16:25: A clinical view on BET inhibition in targeting
residual risk in CVD and diabetesKausik Ray, MD
16:25 – 16:30: Discussion & summaryCo-ChairmenKausik Ray,
MDUlrich Laufs, MD
Symposium presentations and videos will be posted to the Company
website HERE once available.
Satellite Symposium Educational
Objectives
- To summarize the epidemiology and pathophysiology of patients
at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular
risk in patients with diabetes and CVD
- To review how BET inhibition affects gene expression via
epigenetic mechanisms, as a novel strategy to improve outcomes in
CVD
- To update and review current clinical research programmes
evaluating the role of epigenetic regulation of gene expression in
CVD management
In addition to the satellite symposium, Dr. Ewelina Kulikowski,
Senior Vice President of Research & Development of Resverlogix
will provide an oral presentation during the Basic and
Translational Science Hot Line - Vascular Biology session on Aug.
27, 2018 at 15:00 (local time), titled: Apabetalone (RVX-208)
Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key
Vascular Inflammation Markers in Monocytes, Endothelial Cells and
in Inflamed Mouse Aorta.
In Other News
Resverlogix will be participating at the following upcoming
conferences:
- 20th Annual Rodman & Renshaw Global Investment Conference,
September 4-6, 2018, New York City
- NewsMakers in the Biotech Industry, September 7th, 2018, New
York City
- BIO Investor Forum, October 17-18, 2018, San Francisco
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is a BET inhibitor selective for
the second bromodomain (BD2) within the BET proteins. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease, diabetes mellitus,
chronic kidney disease, end-stage renal disease treated with
hemodialysis, neurodegenerative disease, Fabry disease, peripheral
artery disease and other orphan diseases, while maintaining a well
described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations Email: ir@resverlogix.com Phone:
403-254-9252Or visit our website: www.resverlogix.com
This news release may contain certain
forward-looking information as defined under applicable Canadian
securities legislation, that are not based on historical fact,
including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should",
"expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward
looking information relating to the potential role of apabetalone
in the treatment of CVD, DM, chronic kidney disease, end-stage
renal disease treated with hemodialysis, Alzheimer's disease, Fabry
disease, and Orphan diseases. Our actual results, events or
developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no
assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject
to numerous assumptions and risk factors including those discussed
in our Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this
news release are expressly qualified by this cautionary statement
and are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024